NOS2 and non-small cell lung carcinoma: Recently, the combination of CpG oligodeoxynucleotides (CpG; TLR9 agonist) with Ferumoxytol® (FMT; an FDA approved drug for the treatment of iron deficiency) showed a synergistic antitumoral effect, mediated by an increased infiltration of M1-like macrophages (expressing F4/80 and iNOS) in a murine model of NSCLC [128].